Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis

by Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD, Sarayut Geater, MD, Chong-Jen Yu, MD, PhD, Chun-Ming Tsai, MD, Te-Chun Hsia, MD, Jun Chen, MD, PhD, Meng-Chih Lin, MD, You Lu, MD, Virote Sriuranpong, MD, Cheng-Ta Yang, MD, Paramita Sen, PhD, Fabrice Branle, MD, Michael Shi, MD, Yi-Long Wu, MD
Published 2021-03-01

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

by James Chih-Hsin Yang, MD, PhD, Karen L. Reckamp, MD, Young-Chul Kim, MD, PhD, Silvia Novello, MD, PhD, Egbert F. Smit, MD, PhD, Jong-Seok Lee, MD, PhD, Wu-Chou Su, MD, Wallace L. Akerley, MD, Collin M. Blakely, MD, PhD, Harry J.M. Groen, MD, PhD, Lyudmila Bazhenova, MD, Enric Carcereny Costa, MD, Rita Chiari, MD, PhD, Te-Chun Hsia, MD, PhD, Tony Golsorkhi, MD, Darrin Despain, MStat, Danny Shih, BA, Sanjay Popat, BSc, MBBS, FRCP, PhD, Heather Wakelee, MD
Published 2021-02-01